Sleep disturbances and non-cyclical breast pain: where to break the vicious cycle?

PURPOSE: This study aimed to assess the sleep quality of patients with the complaint of non-cyclical breast pain (NCBP), compare them to a healthy control group, and analyze the interrelationship of sleep quality with pain, anxiety, depression, and quality of life. METHODS: This cross-sectional study was conducted in consecutive women presenting to the general surgery clinic between May 2020 and December 2020. Patients diagnosed with NCBP formed one group for study and 44 receiving routine well-woman care formed the control group. Evaluations were undertaken using the Nottingham Health Profile (NHP), short-form McGill Pain Questionnaire (SF-MPQ), Hospital Anxiety and Depression Scale (HADS), and Pittsburgh Sleep Quality Index (PSQI). RESULTS: Of 160 consecutive patients, 116 were diagnosed with NCBP and 44 controls. Poor sleep quality (PSQI > 5) was present in 59% (n = 69) of the women with NCBP and 38% (n = 17) of the controls (p = 0.018). According to PSQI global score, overall sleep quality was significantly lower in the NCBP group compared to the control group (p < 0.007). Sleep latency, sleep duration, and daytime dysfunction were the major components determining the PSQI global score (p = 0.004, p = 0.004, and p < 0.001, respectively). The correlation matrix revealed a statistically significant correlation between the HAD-A, HAD-D, and SF-MSQ and NHP subgroups and PSQI global score in the NCBP group (p < 0.001) whereas this significant correlation was detected with only the NHP subgroups among the controls. CONCLUSIONS: A considerable proportion of NCBP patients, regardless of sensory or affective characteristics and trajectory of pain, experience significant sleep disturbances. Further studies should be conducted to evaluate the existence of central sensitization syndrome in NCBP patients to determine the required pharmacological treatment.

Eficacia y seguridad de eplerenona en pacientes varones con insuficiencia cardiaca crónica con fracción de eyección reducida, clase funcional II-IV NYHA y recibiendo terapia médica óptima y que presentan ginecomastia con mastodinia debido al uso de espironolactona / Efficacy and safety of eplerenone in male patients with chronic heart failure with reduced ejection fraction, NYHA functional class II-IV and receiving optimal medical therapy and presenting with gynecomastia with mastodynia due to the use of spironolactone

INTRODUCCIÓN: El presente dictamen expone la evaluación de la eficacia y seguridad de eplerenona como tratamiento en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida < 35 %, clase funcional NYHA II-IV y con terapia óptima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. La insuficiencia cardiaca (IC) es un conjunto de síntomas y signos que resultan de anormalidades estructurales y/o funcionales de la función cardiaca y que conducen a un gasto cardiaco reducido o altas presiones de llenado al reposo o con esfuerzo. Se clasifica según la fracción de eyección del ventrículo izquierdo (FEVI) como IC con fracción de eyección reducida (ICFEr) o IC con fracción de eyección preservada (ICFEp). La ICFEr tiene una FEVI < 40 %. Todos los pacientes con ICFEr clase NYHA II-IV deben iniciar tratamiento con un inhibidor de la enzima convertidora de angiotensina (IECA) o un bloqueador del receptor de la angiotensina II (ARA II), y un beta bloqueador (BB). Se debe agregar a este esquema un antagonista de los receptores de mineralocorticoides (ARM). El ARM disponible en EsSalud es la espironolactona. Sin embargo, algunos pacientes pueden sufrir el evento adverso de ginecomastia con dolor mamario con su uso, afectando de manera negativa las actividades diarias y la calidad de vida. Según opinión de los especialistas en cardiología, esta situación podría impactar también en la adherencia al tratamiento. OBJETIVO: evaluar la eficacia y seguridad de eplerenona como tratamiento en pacientes con insuficiencia cardiaca crónica con FEVI < 35 %, clase funcional NYHA II-IV y con terapia óptima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. METODOLOGÍA: La búsqueda de la literatura científica se realizó con el objetivo de identificar evidencia sobre eplerenona en el tratamiento de los pacientes con insuficiencia cardiaca crónica con fracción de eyección reducida < 35 %, clase funcional NYHA II-IV y con terapia óptima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. La búsqueda de la literatura científica identificó tres GPC (ESC 2021, NICE 2018 y SIGN 2016) y cuatro ensayos clínicos aleatorizados (ECA); tres de ellos fueron controlados con placebo y uno comparó eplerenona con espironolactona. Los tres primeros fueron el estudio RALES que evaluó a espironolactona, el estudio EMPHASIS-HF que evaluó a eplerenona y el estudio J-EMPHASIS-HF que evaluó la eplerenona. El cuarto ensayo comparó espironolactona con eplerenona (Khondokar 2020). RESULTADOS: Se llevó a cabo una búsqueda de evidencia científica relacionada al uso de eplerenona como tratamiento en pacientes con IC crónica con FEVI < 35 %, clase funcional NYHA II-IV y con terapia óptima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. En la presente sinopsis se describe la evidencia disponible según el tipo de publicación, siguiendo lo indicado en los criterios de elegibilidad (GPC, ETS, RS, MA y ECA fase III). CONCLUSIONES: En el presente documento, se evaluó la mejor evidencia científica disponible hasta la actualidad en relación con la eficacia y seguridad de eplerenona como tratamiento en pacientes con insuficiencia cardiaca crónica con fracción de eyección reducida < 35%, clase funcional NYHA II-IV y con terapia óptima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. La eplerenona ejerce su acción al unirse a los receptores de mineralocorticoides y de esta manera impide su unión a la aldosterona. Eplerenona está contraindicado en los pacientes con: 1) Potasio > 5.5 mEq/L al inicio, 2) Depuración de creatinina ≤ 30 mL/min. Una diferencia importante con la espironolactona es la alta selectividad que tiene eplerenona por los receptores de aldosterona. La introducción del grupo epoxi presente en la eplerenona afecta solo marginalmente su afinidad por los receptores de mineralocorticoides, pero disminuye su afinidad por los receptores de andrógenos y progesterona tres a diez veces menor que el de aldosterona. Todas las guías clínicas consultadas recomiendan agregar un ARM como la espironolactona o eplerenona, al tratamiento óptimo con BB y IECA/ARAII, en pacientes con ICFEr, clase funcional NYHA II-IV, para mejorar su sobrevida. Además, las GPC recomiendan que los clínicos deben considerar cambiar a eplerenona en pacientes que experimentan ginecomastia tomando espironolactona, pero este cambio debe ser considerado como parte de una toma de decisiones compartida, ya que la valoración en evitar la aparición de ginecomastia varia de paciente a paciente. El primer ARM fue espironolactona y fue estudiado en el ECA de Pitt et 1999 (RALES), que evaluó los efectos de agregar espironolactona al régimen recomendado en pacientes con ICFEr y síntomas moderados a severos (clase funcional NYHA III o IV). Comparado con placebo, la adición de espironolactona al régimen de primera línea disminuyó la tasa de muerte por cualquier causa y el riesgo de hospitalización por causas cardiovasculares, comparado con placebo. Posteriormente, se desarrolló otro ARM: eplerenona que fue comparado con placebo en el estudio EMPHASIS-HF, el cual incluyó a pacientes menos sintomáticos (NYHA II) con tratamiento óptimo. La eplerenona redujo el riesgo de muerte por cualquier causa y la hospitalización total, comparado con placebo. Por lo expuesto, el IETSI aprueba el uso de eplerenona como tratamiento en pacientes con insuficiencia cardiaca crónica con FEVI < 35 %, clase funcional NYHA II-IV y con terapia optima, que desarrollan ginecomastia con mastodinia debido a uso de espironolactona. La vigencia del presente dictamen es de dos años, según lo establecido en el Anexo N° 1 y la continuación de dicha aprobación estará sujeta a la evaluación de los resultados obtenidos y de mayor evidencia que pueda surgir en el tiempo.

Autoimmune syndrome induced by adjuvants after breast enhancement with polyacrylamide hydrogel: a study in Poland.

Autoimmune syndrome induced by adjuvants (ASIA) is the spectrum of diseases in which the substances considered inert to the body induce autoimmune reactions and inflammation. Some of the biomaterials recently used in plastic surgery, such as silicone or polyacrylamide hydrogel (PAAG) seem to trigger clinical features of ASIA. The aim of this study was to assess the incidence of these features within a group of women after breast augmentation with PAAG. As many as 30 consecutive patients (26-59 years, mean age 39.5) referred to the Clinic of Plastic Surgery after breast enhancement with PAAG were examined. The validated criteria of ASIA syndrome were employed. Descriptive statistics were chosen based on the distribution of variables. The research was approved by the Bioethical Committee of the Centre of Postgraduate Medical Education in Warsaw, Poland. Within the studied group, 50% of patients (n = 15) fulfilled ASIA diagnostic criteria. Apart from local complications, we encountered various general symptoms, among which fever (n = 13, 43.3%), tingling and numbness of upper extremities (n = 10, 33.3%) and chronic fatigue (n = 9, 30%) were the most common. These symptoms were present on an ambulatory visit, before qualification to the operation of hydrogel removal. All patients undergoing surgical PAAG removal (n = 8) declared alleviation or complete resolution of the symptoms. Polyacrylamide hydrogel breast filling, although limiting the invasiveness of the procedure in relation to silicone breast implants, also carries the risk of developing ASIA symptoms. The removal of PAAG may bring improvement in some cases.

Breast pain affects the performance of elite female athletes.

Although breast pain is problematic for many active women, no published research has investigated breast pain experienced by elite female athletes. This study aimed to examine the extent that mastalgia and exercise-induced breast pain affected the sporting performance of elite female athletes during training and competition. A custom-designed online survey with questions related to sport participation, as well as the frequency, severity and perceived performance effects of mastalgia and exercise-induced breast pain, was distributed to sporting organisations, coaches, medical staff and teams/clubs throughout Australia. Five hundred and forty female athletes competing nationally or internationally across 49 different sports participated in the survey. Sixty-three percent of respondents reported experiencing breast pain associated with their menstrual cycle and 33% reported that this pain worsened during activity. Forty-four percent of athletes reported experiencing exercise-induced breast pain during training or competition. Both types of breast pain were also reported to negatively affect sporting performance (20% and 32%, respectively). Mastalgia associated with the menstrual cycle and exercise-induced breast pain should be acknowledged as potential problems affecting the sporting performance of elite female athletes. Awareness around the impact of breast pain and the development and implementation of breast pain management strategies are essential for this population.

Breast tuberculosis in East London: A 13-year retrospective observational study.

SETTING: Breast tuberculosis (TB) is rare in Western Europe, and its diagnosis may be delayed through lack of awareness of presenting features. Our institution serves a large East London population with a high incidence of TB. OBJECTIVE: To characterize presenting features and avoidable diagnostic delay in breast TB patients. DESIGN: We conducted a 13-year retrospective study of breast TB patients treated at our institution including demographic, clinical, microbiology, and pathology data. RESULTS: Forty-seven cases were included; 44 (94%) were female, with a median age of 33 years (IQR 28.5-39.5). The main presenting feature was a breast lump in 41 cases (87%); which were predominantly solitary unilateral lesions (25, 61%) and frequently located in the upper outer quadrant (28, 68%). Where performed, Mycobacterium tuberculosis was cultured in 15/36 (42%) cases. Granulomata were present on biopsy or aspirate in 21 (47%) and 17 (36%) cases, respectively. The median duration between symptom onset and treatment was 20 weeks (IQR 15-30). Forty-six (98%) completed treatment successfully and one relapsed. CONCLUSION: A high index of suspicion for TB is required for individuals presenting with breast symptoms from countries where TB is endemic. Development of standardized pathways may improve detection and management of breast TB may reduce diagnostic delay.

Quantitative Sensory Testing, Antihistamines, and Beta-Blockers for Management of Persistent Breast Pain: A Case Series.

BACKGROUND: It is not uncommon for mothers to have persistent pain with breastfeeding beyond the first few weeks after birth. Persistent pain can be multifactorial, with neuropathic pain maintained by central sensitization being one dimension. Our knowledge in delineating categories of persistent pain is simple and not very sophisticated. METHODS: We have developed and tested a Lactation Quantitative Sensory Test (L-QST) to quantify the neuropathic component of persistent breastfeeding pain. We present three case reports of neuropathic breastfeeding pain and treatment, and we discuss the potential role of histamine and catecholamines in persistent breastfeeding-associated pain. CONCLUSIONS: The L-QST can be a useful tool to quantify neuropathic pain. Further studies are needed to test inter-observer reliability and reproducibility of this tool. Antihistamines can be considered for treating persistent pain in breastfeeding women with a history of allergy or atopy, and beta-blockers may be helpful in women with multiple pain disorders.

Behavioral and patho-physiological response as possible signs of pain in dairy cows during Escherichia coli mastitis: A pilot study.

Bovine mastitis is one of the most common diseases in the dairy industry and it is a major welfare problem. Pain during mastitis is generally assessed through behavior but a combination of indicators would increase the chances of detecting pain and assessing its intensity. The aim of this study was to assess behavioral and patho-physiological responses as possible signs of pain experienced by cows after experimental intramammary challenge (mastitis) with Escherichia coli. Six Holstein-Friesian cows received an inoculation of E. coli P4 in one healthy quarter. Evolution of the disease was assessed using bacteriological growth and somatic cell counts (SCC). Cows' response to the challenge was monitored by direct behavioral and clinical observations, data loggers, rumen temperature sensors, and indicators of inflammation, stress, and oxidative status. From all data recorded, the variables that contributed most to the discrimination of mastitis phases were obtained by factorial discriminant analysis. Baseline levels of all indicators corresponded to values before challenge. Specifically, we weighted data relating to lying behavior by the observations at the same hour of the day before challenge to eliminate the circadian rhythm effect. We identified 3 phases that were discriminated by factorial discriminant analysis with good performance. Nine indicators varied according to the phase of the disease: cows' attitude toward their surroundings, tail position, clinical signs, ear position, variation of postural changes, concentrations of haptoglobin and serum amyloid A (SAA), cortisol blood levels, and rumen temperature (as a surrogate for body temperature). In phase 1 (4 to 8 h postinoculation), E. coli proliferated exponentially in milk but inflammation indicators remained at baseline levels. Cows were less attentive toward their surroundings (median score, 0.63), and postural changes (lying/standing) were less frequent (0.75 times from baseline). In phase 2 (12 to 24 h postinoculation), bacterial concentrations peaked around 12 h and then began to decrease concomitantly with a sharp SCC increase. Cows were less attentive toward their surroundings (score, 0.54), had high plasma cortisol (31.3 ng/mL) and SAA (100.3 µg/mL) concentrations, and rumen temperature was increased (40.3°C). In phase 3 (32 to 80 h postinoculation), bacterial concentrations decreased concomitantly with high SCC levels. Cows had high levels of haptoglobin (0.57 mg/mL) and SAA (269 µg/mL) but showed no behavioral changes. Dairy cows displayed changes of behavioral, inflammatory, and stress parameters after E. coli mammary inoculation. Our results suggest that cows may have experienced discomfort in the preclinical phase (phase 1) and pain in the acute phase (phase 2) but neither discomfort nor pain in the remission phase (phase 3). Although larger controlled studies are needed to confirm our findings, this knowledge could be useful for early detection of E. coli mastitis and for decision-making regarding the initiation of pain-relief treatment during mastitis in dairy cows. This would improve animal welfare and potentially faster disease remission.

Predictors of Altered Upper Extremity Function During the First Year After Breast Cancer Treatment.

OBJECTIVE: The purpose of this study was to evaluate trajectories of and predictors for changes in upper extremity (UE) function in women (n = 396) during the first year after breast cancer treatment. DESIGN: Prospective, longitudinal assessments of shoulder range of motion (ROM), grip strength, and perceived interference of function were performed before and for 1 year after surgery. Demographic, clinical, and treatment characteristics were evaluated as predictors of postoperative function. RESULTS: Women had a mean (SD) age of 54.9 (11.6) years, and 64% were white. Small but statistically significant reductions in shoulder ROM were found on the affected side over 12 months (P < 0.001). Predictors of interindividual differences in ROM at the 1-month assessment were ethnicity, neoadjuvant chemotherapy, type of surgery, axillary lymph node dissection, and preoperative ROM. Predictors of interindividual differences in changes over time in postoperative ROM were living alone, type of surgery, axillary lymph node dissection, and adjuvant chemotherapy. Declines in mean grip strength from before through 1 month after surgery were small and not clinically meaningful. Women with greater preoperative breast pain interference scores had higher postoperative interference scores at all postoperative assessments. CONCLUSION: Some of the modifiable risk factors identified in this study can be targeted for intervention to improve UE function in these women.

Can mastalgia be another somatic symptom in fibromyalgia syndrome?

OBJECTIVE: The purposes of this study were to determine the coexistence of mastalgia and fibromyalgia, to investigate the effects of this combination on pain patterns, and to discuss the status of breast pain in the diagnostic algorithm of fibromyalgia syndrome. METHODS: Sixty-one female patients reporting breast pain during the last three months and 53 female patients diagnosed with fibromyalgia syndrome were enrolled in this study. The Breast Pain Questionnaire was administered to all participants in the mastalgia group and to those in the fibromyalgia syndrome group who had experienced mastalgia during the past three months. The patients in the fibromyalgia syndrome group were evaluated using the 2010 preliminary American College of Rheumatology classification criteria. All of the patients in the mastalgia group were evaluated for the diagnosis of fibromyalgia syndrome by a single physiatrist. The coexistence and pain patterns of mastalgia and fibromyalgia were assessed statistically. RESULTS: Approximately half of the patients with fibromyalgia syndrome (47.2%) reported having mastalgia at the time of admission and 37.7% of the patients with mastalgia met the diagnostic criteria for fibromyalgia syndrome. The patients with mastalgia in the fibromyalgia syndrome group had significantly higher total breast pain scores compared with the women in the mastalgia group. In addition, the patients with fibromyalgia syndrome in the mastalgia group had significantly higher Widespread Pain Index and Symptom Severity Scale scores than the patients with fibromyalgia syndrome. CONCLUSIONS: We suggest that mastalgia can be an aspect of the central sensitivity syndrome and can be added to the somatic symptoms of fibromyalgia.

Can mastalgia be another somatic symptom in fibromyalgia syndrome?

OBJECTIVE: The purposes of this study were to determine the coexistence of mastalgia and fibromyalgia, to investigate the effects of this combination on pain patterns, and to discuss the status of breast pain in the diagnostic algorithm of fibromyalgia syndrome. METHODS: Sixty-one female patients reporting breast pain during the last three months and 53 female patients diagnosed with fibromyalgia syndrome were enrolled in this study. The Breast Pain Questionnaire was administered to all participants in the mastalgia group and to those in the fibromyalgia syndrome group who had experienced mastalgia during the past three months. The patients in the fibromyalgia syndrome group were evaluated using the 2010 preliminary American College of Rheumatology classification criteria. All of the patients in the mastalgia group were evaluated for the diagnosis of fibromyalgia syndrome by a single physiatrist. The coexistence and pain patterns of mastalgia and fibromyalgia were assessed statistically. RESULTS: Approximately half of the patients with fibromyalgia syndrome (47.2%) reported having mastalgia at the time of admission and 37.7% of the patients with mastalgia met the diagnostic criteria for fibromyalgia syndrome. The patients with mastalgia in the fibromyalgia syndrome group had significantly higher total breast pain scores compared with the women in the mastalgia group. In addition, the patients with fibromyalgia syndrome in the mastalgia group had significantly higher Widespread Pain Index and Symptom Severity Scale scores than the patients with fibromyalgia syndrome. CONCLUSIONS: We suggest that mastalgia can be an aspect of the central sensitivity syndrome and can be added to the somatic symptoms of fibromyalgia.

Breast motion asymmetry during running.

Breast asymmetry is common in females, despite a similar driving force; dynamic activity may result in asymmetrical breast motion. This preliminary study investigated how breast categorisation (left/right or dominant/non-dominant) may affect breast support recommendations and its relationship with breast pain. Ten females ran on a treadmill at 10 kph in three breast supports (no bra, everyday bra, sports bra). Five reflective markers on the thorax and nipples were tracked using infrared cameras (200 Hz) during five running gait cycles in each breast support. Multiplanar displacements of both breasts were calculated relative to the thorax. Although the maximum individual participant difference was 2.4 cm (mediolaterally) between the left and right breast, no left/right differences were found in any direction or support condition. Notably, correlations between breast pain and anterioposterior breast displacement were stronger with the left breast (r = 0.614) and moderate with the right breast (r = 0.456). Following participant categorisation according to the greatest magnitude of superioinferior breast displacement (dominant breast), results showed significant differences in displacement for all directions across different breast supports. When using breast kinematic data to examine relationships with breast pain or to recommend breast support requirements, data on both breasts should be collected.

[Mastodynia. Premenstrual syndrome].

Mastodynia is defined as breast tenderness and pain, also called mastalgia. There are several types of cyclic, noncyclic and extramammary. The cyclic mastodynia is the most common one, and represents a clinical symptom of the premenstrual syndrome and of the more severe premenstrual dysphoric disorder. The article outlines different types of mastalgia with their typical clinical features, including the relatively rear Tietze's syndrome and MONDOR'S disease, as well as the PMS and the PMDD. The authors also offer a diagnostic algorithm and specific diagnostic criteria. There is also a discussion on the main treatment alternatives being symptomatic treatment of the most troublesome symptoms or alteration of the menstrual cycle and a brief discussion on the pharmaceutical preparations used for treatment including the administration of selective serotonin reuptake inhibitors (SSRI).

The experience of breast pain (mastalgia) in female runners of the 2012 London Marathon and its effect on exercise behaviour.

BACKGROUND: For female marathon runners, breast pain (mastalgia) may be an important issue which has yet to be considered. This study aimed to determine the prevalence and severity of mastalgia in female marathon runners, identify factors that increase mastalgia and methods used to overcome mastalgia, and explore the impact that mastalgia may have on marathon training. METHODS: 1397 female marathon runners were surveyed at the 2012 London Marathon Registration. All participants who completed the four-part, 30-question survey in its entirety have been included in the analysis (n=1285). RESULTS: 32% of participants experienced mastalgia. This was significantly related to cup size and was greater during vigorous compared with moderate physical activity. Exercise-related factors were the primary factors reported to increase mastalgia participation. Seventeen per cent of symptomatic participants reported that mastalgia affected their exercise behaviour. Methods reportedly used to overcome mastalgia included pain medication and firm breast support; however, 44% of participants took no measures to relieve symptoms despite over half describing their mastalgia as discomforting. CONCLUSIONS: Mastalgia was experienced by a third of marathon runners and was found to be related to breast size which has previously been unreported. The link between exercise and mastalgia has yet to be established; however, this study identified that exercise was the most prevalent factor in mastalgia occurrence which may have implications for its management. The number of participants who took no measures to relieve their mastalgia, or resorted to pain medication, highlights the importance and significance of research into exercise-related mastalgia.

Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment.

PURPOSE: The aim of our study was to establish the prevalence of breast pain persisting 5 years after the initial treatment of breast cancer (BC) and the relationship between those persistent symptoms and general well-being. METHODS: The study involved women from Victoria, Australia, who had survived at least 5 years from diagnosis, remained free from recurrence or new BC and completed the fifth annual follow-up questionnaire. Analysis involved both multivariable logistic and linear regression. RESULTS: Of 1,205 women, 45 % reported breast pain which persisted for at least 3 months following initial treatment, and of these, 80 % reported pain persisting for at least 5 years. The factor contributing most to the likelihood of persistent breast pain was current lymphedema; however, a full multivariable model explained <10 % of the likelihood of breast pain persisting for 5 years. The presence of breast pain at 5 years was associated with only a modest reduction in general well-being. CONCLUSIONS: Breast pain persisting for at least 5 years after treatment for BC is common. As the pain is largely unexplained by factors associated with the characteristics of the cancer or its treatment, the contribution of patient expectations to persistent breast pain may be considerable. IMPLICATIONS FOR CANCER SURVIVORS: Where persistent pain occurs, referral for the management of pain and, where appropriate, lymphedema is warranted.

Effectiveness of external Sanjierupi Gao on mastalgia caused by mammary gland hyperplasia: a placebo controlled trial.

OBJECTIVE: To evaluate the curative effect of external application of the Chinese drug, Sanjierupi Gao, on mastalgia caused by mammary gland hyperplasia. METHODS: This randomized, double-blinded, and placebo controlled study enrolled 260 patients with mammary gland hyperplasia from five hospitals. Patients were randomly and equally divided into a Sanjierupi Gao treatment group and a placebo control group. An adhesive plaster was applied to the most painful area on either breast for 7 h a day. Treatment lasted for two menstrual cycles without application during menstruation. Mastalgia was used as the main index of curative effect. The change before and after treatment in days of mastalgia, the time to alleviate pain, pain extent, and severe pain scores were observed. RESULTS: Compared to the control group, the treatment group had significantly fewer days of mastalgia (P < 0.01), a significantly lower severe pain score (P < 0.01), and significantly less subjective pain and tenderness (P < 0.05 and P < 0.01, respectively). Three days before the follow-up visit, the pain score in the treatment group was significantly lower than that in the control group (P < 0.05). A non-parametric test was used to compare the time to alleviate mastalgia between the two groups and found no statistical difference (Z = -0.313, P = 0.754). CONCLUSION: Application of Sanjierupi Gao can decrease mastalgia duration in patients with mammary gland hyperplasia during menstruation and alleviate the extent of mastalgia. The time to alleviate pain is psychologically influenced.

Breast disorders in the female adolescent.

Breast disorders in the adolescent female can cause significant anxiety for the patient and her family and pose a clinical challenge for her health care provider. Care and consideration given to the emotions of the patient and family, as well as minimizing trauma and injury to the developing breast, are paramount. This article addresses the gamut of concerns that involve the adolescent breast. As benign breast disease is the most common breast disorder, conservative management should be entertained whenever possible. Patients should be referred to providers comfortable in treating the adolescent patient with breast disease or concerns.